Altered expression of cell cycle regulators in adult T-cell leukemia/lymphoma patients

Authors

  • Abbas Shirdel Hematology Department, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Abolghasem Allahyari Hematology Department, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Amin Golabpour Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, Iran
  • Ehsan Ghayour Karimani Molecular Diagnostic Unit, Research and Education Department, Razavi Hospital, Mashhad, Iran.
  • Hossein Rahimi Hematology Department, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Houshang Rafatpanah Inflammation and Inflammatory Diseases Research Centre, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Khadijeh Jamialahmadi Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran - Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Kobra Etminani Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, Iran.
  • Mohammad Mehdi Akbarin Inflammation and Inflammatory Diseases Research Centre, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Reza Torshizi Department of Modern Sciences and Technologies, Molecular Medicine Department, Faculty of Medicine, Mashhad University of Medical sciences, Mashhad, Iran.
Abstract:

Abstract Background: Adult T-cell leukemia/lymphoma (ATLL) is caused by human T-cell lymphotropic virus type-1 (HTLV-1).  HTLV-1 oncogenes can induce malignancy through controlled gene expression of cell cycle checkpoints in the host cell. HTLV-I genes play a pivotal role in overriding cell cycle checkpoints and deregulate cellular division. In this study, we aimed to determine and compare the HTLV-1 proviral load and the gene expression levels of cyclin-dependent kinase-2 (CDK2), CDK4, p53, and retinoblastoma (Rb) in ATLL and carriers groups. Methods: A total of twenty-five ATLL patients (12 females and 13 males) and 21 asymptomatic carriers (10 females and 11 males) were included in this study. TaqMan real-time polymerase chain reaction assay was used for evaluation of proviral load and gene expression levels of CDK2, CDK4, p53, and Rb. Statistical analysis was used to compare proviral load and gene expression levels between two groups, using SPSS version 18. Results: The mean scores of the HTLV-1 proviral load in the ATLL patients and healthy carriers were 13067.20±6400.41 and 345.79±78.80 copies/104 cells, respectively (P=0.000). There was a significant correlation between the gene expression levels of CDK2 and CDK4 (P=0.01) in the ATLL group. Conclusions: Our findings demonstrated a significant difference between the ATLL patients and healthy carriers regarding the rate of proviral load and the gene expression levels of p53 and CDK4; accordingly, proviral load and expression levels of these genes may be useful in the assessment of disease progression and prediction of HTLV-1 infection outcomes. 

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Absence of FLT3 mutations in Iranian adult T-cell leukemia/lymphoma patients

Background: Adult T cell leukemia lymphoma (ATLL) is a rare disease, significantly linked to the infection by the human T-cell lymphotropic virus 1(HTLV-1). ATLL is typically preceded by decades of clinical latency during which infected cells accumulate selectable traits leading to a malignant transformation. Amongst all the HTLV-1 infected carriers only about 3-5% will develop ATLL. Despite th...

full text

Specific cutaneous manifestations in adult T cell leukemia/lymphoma

Background and aim: Adult T cell leukemia/lymphoma (ATLL) is an aggresive malignancy which may occur in human T lymphotropic virus1(HTLV1) infected persons. HTLV1 is endemic in Khorasan with prevalence of 2.3% in general population. Since specific cutaneous manifestations of lymphoma may occur in a significant number of patients, we studied ATLL patients in Mashhad.Mate...

full text

Expression of cell-cycle regulators during Xenopus oogenesis.

In full-grown Xenopus oocytes, cell-cycle regulators and an inactive form of maturation/M phase promoting factor (pre-MPF) are stored ready to bring about a specific cell cycle for oocyte maturation. We examined the expression pattern of these cell-cycle regulators as well as pre-MPF formation during oogenesis. Cdc2 and Cyclin B2 were already present in stage I oocytes and pre-MPF formation was...

full text

SnapShot: Cell-Cycle Regulators II

function S. cerevisiae (Budding Yeast) S. pombe (fission Yeast) D. melanogaster (fruit fly) X. laevis (clawed Toad) H. sapiens (Human) Cdk-inhibitory kinases Phosphorylate Cdk in active site, blocking activity swe1 Wee1, Mik1 Dwee1, Dmyt1 Wee1, Myt1 Wee1, Myt1 Cdk-activating phosphatases Dephosphorylate inhibitory phosphorylation of Cdk subunit

full text

SnapShot: Cell-Cycle Regulators I

function Phase S. cerevisiae (Budding Yeast) S. pombe (fission Yeast) D. melanogaster (fruit fly)

full text

Targeting cell cycle regulators in hematologic malignancies

Hematologic malignancies represent the fourth most frequently diagnosed cancer in economically developed countries. In hematologic malignancies normal hematopoiesis is interrupted by uncontrolled growth of a genetically altered stem or progenitor cell (HSPC) that maintains its ability of self-renewal. Cyclin-dependent kinases (CDKs) not only regulate the mammalian cell cycle, but also influence...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 6  issue 1

pages  88- 94

publication date 2017-10

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023